Sec Form 4 Filing - Eansor Norman David @ BIO-TECHNE Corp - 2020-08-09

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Eansor Norman David 2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [ TECH] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) President-Protein Sciences (Last) (First) (Middle) 8100 SOUTHPARK WAY, A-8 3. Date of Earliest Transaction (MM/DD/YY) 08/09/2020 (Street) LITTLETON, CO80120 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 08/09/2020 M 2,174 A $ 0 2,174 D Common Stock 08/09/2020 F 856 D $ 265.76 1,318 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Restricted Stock Units ( 1 ) 08/09/2020 M 2,174 ( 2 ) ( 2 ) Common Stock 2,174 $ 0 0 D Stock Options (Right to Buy) $ 106.59 ( 3 ) 08/18/2023 Common Stock 14,114 14,114 D Stock Options (Right to Buy) $ 106.59 ( 4 ) 08/18/2023 Common Stock 18,819 18,819 D Stock Options (Right to Buy) $ 125.05 ( 3 ) 08/09/2024 Common Stock 11,982 11,982 D Stock Options (Right to Buy) $ 125.05 ( 5 ) 08/09/2024 Common Stock 15,976 15,976 D Restricted Stock Units ( 1 ) ( 6 ) ( 6 ) Common Stock 2,537 2,537 D Stock Options (Right to Buy) $ 177.32 ( 6 ) 08/08/2025 Common Stock 13,550 13,550 D Stock Options (Right to Buy) $ 177.32 ( 7 ) 08/08/2025 Common Stock 18,066 18,066 D Restricted Stock Units ( 1 ) ( 8 ) ( 8 ) Common Stock 3,151 3,151 D Stock Options (Right to Buy) $ 190.41 ( 8 ) 08/07/2026 Common Stock 15,948 15,948 D Stock Options (Right to Buy) $ 190.41 ( 9 ) 08/07/2026 Common Stock 21,265 21,265 D Restricted Stock Units ( 1 ) ( 10 ) ( 10 ) Common Stock 2,575 2,575 D Stock Options (Right to Buy) $ 267.87 ( 10 ) 08/05/2027 Common Stock 11,488 11,488 D Stock Options (Right to Buy) $ 267.87 ( 11 ) 08/05/2027 Common Stock 15,318 15,318 D Stock Options (Right to Buy) $ 267.87 ( 12 ) 08/05/2027 Common Stock 24,975 24,975 D Stock Options (Right to Buy) $ 267.87 ( 13 ) 08/05/2027 Common Stock 24,975 24,975 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Eansor Norman David 8100 SOUTHPARK WAY, A-8 LITTLETON, CO80120 President-Protein Sciences Signatures /s/ Brenda S. Furlow as Attorney-in-Fact for N. David Eansor pursuant to Power of Attorney previously filed. 08/11/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. ( 2 )On 8/9/2020, the Board of Directors certified vesting of 2,174 performance RSUs. ( 3 )Fully exercisable. ( 4 )Options to purchase 4,705 shares vest on each of 8/18/2017, 8/18/2018 and 8/18/2019 and options to purchase 4,704 shares vest on 8/18/2020. ( 5 )Options to purchase 3,994 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and 8/9/2021. ( 6 )Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). ( 7 )Options to purchase 4,517 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 4,516 shares vest on each of 8/8/2021 and 8/8/2022. ( 8 )Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). ( 9 )Options to purchase 5,317 shares vest on 8/7/2020 and options to purchase 5,316 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023. ( 10 )Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). ( 11 )Options to purchase 3,830 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 3,829 shares vest on each of 8/5/2023 and 8/5/2024. ( 12 )Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021 ( 13 )Options to purchase 8,325 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.